GAPDH and early-onset autosomal dominant Alzheimer disease: It was reported that RVG-vectorized EVs loaded with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) siRNA successfully delivered the therapeutic siRNA in wild-type mice to the cells of neurovascular unit and caused efficient knock down of BACE1, which represents a therapeutic target in Alzheimer’s disease [114].